<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>AI Disruption Forecast: Sanofi ‚Äî Employee Perspective | The 2030 Intelligence Report</title>
    <meta name="description" content="---">
    <meta property="og:title" content="SANOFI SA: TRANSFORMATION FROM PHARMA CONSOLIDATOR TO SPECIALTY-VACCINES LEADER">
    <meta property="og:description" content="---">
    <meta property="og:type" content="article">
    <meta property="og:url" content="https://ai2030report.com/articles/companies-europe-sanofi-sanofi-employee.html">
    <meta property="og:image" content="https://ai2030report.com/og/companies-europe-sanofi-sanofi-employee.png">
    <meta property="og:image:width" content="1200">
    <meta property="og:image:height" content="630">
    <meta name="twitter:card" content="summary_large_image">
    <meta name="twitter:title" content="SANOFI SA: TRANSFORMATION FROM PHARMA CONSOLIDATOR TO SPECIALTY-VACCINES LEADER">
    <meta name="twitter:description" content="---">
    <meta name="twitter:image" content="https://ai2030report.com/og/companies-europe-sanofi-sanofi-employee.png">
    <link rel="canonical" href="https://ai2030report.com/articles/companies-europe-sanofi-sanofi-employee.html">
    <script type="application/ld+json">
    {
        "@context": "https://schema.org",
        "@type": "Article",
        "headline": "SANOFI SA: TRANSFORMATION FROM PHARMA CONSOLIDATOR TO SPECIALTY-VACCINES LEADER",
        "description": "---",
        "url": "https://ai2030report.com/articles/companies-europe-sanofi-sanofi-employee.html",
        "author": {
            "@type": "Organization",
            "name": "The 2030 Intelligence Report"
        },
        "publisher": {
            "@type": "Organization",
            "name": "The 2030 Intelligence Report"
        }
    }
    </script>
    <link rel="icon" href="data:image/svg+xml,<svg xmlns='http://www.w3.org/2000/svg' viewBox='0 0 100 100'><rect rx='20' width='100' height='100' fill='%233b82f6'/><text x='50' y='70' font-size='55' font-weight='700' text-anchor='middle' fill='white'>30</text></svg>">
    <style>
:root {
    --bg-primary: #0a0a0f;
    --bg-secondary: #111118;
    --bg-card: #16161f;
    --bg-card-hover: #1c1c28;
    --border: #2a2a3a;
    --text-primary: #e4e4ef;
    --text-secondary: #9494a8;
    --text-muted: #6b6b80;
    --accent-blue: #3b82f6;
    --accent-purple: #8b5cf6;
    --accent-amber: #f59e0b;
    --accent-green: #10b981;
    --accent-red: #ef4444;
    --accent-cyan: #06b6d4;
    --gradient-1: linear-gradient(135deg, #3b82f6 0%, #8b5cf6 100%);
}

* {
    margin: 0;
    padding: 0;
    box-sizing: border-box;
}

html {
    scroll-behavior: smooth;
}

body {
    font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", Arial, sans-serif;
    background-color: var(--bg-primary);
    color: var(--text-primary);
    line-height: 1.6;
    letter-spacing: -0.3px;
}

a {
    color: var(--accent-blue);
    text-decoration: none;
    transition: color 0.2s ease;
}

a:hover {
    color: var(--accent-purple);
}

button {
    background: none;
    border: none;
    cursor: pointer;
    font-family: inherit;
}

/* Header */
.site-header {
    position: sticky;
    top: 0;
    z-index: 1000;
    background: rgba(10, 10, 15, 0.95);
    backdrop-filter: blur(10px);
    border-bottom: 1px solid var(--border);
}

.header-inner {
    max-width: 1400px;
    margin: 0 auto;
    padding: 1rem 2rem;
    display: flex;
    align-items: center;
    justify-content: space-between;
}

.site-logo {
    display: flex;
    align-items: center;
    gap: 0.5rem;
    font-weight: 700;
    font-size: 1.5rem;
    color: var(--text-primary);
    text-decoration: none;
}

.logo-mark {
    width: 2rem;
    height: 2rem;
    background: var(--gradient-1);
    border-radius: 0.5rem;
    display: flex;
    align-items: center;
    justify-content: center;
    color: white;
    font-weight: 700;
    font-size: 1.2rem;
}

.logo-text {
    display: flex;
    flex-direction: column;
    gap: 0.125rem;
}

.logo-text-main {
    font-size: 1rem;
}

.logo-text-sub {
    font-size: 0.65rem;
    color: var(--text-secondary);
    letter-spacing: 0.5px;
}

.nav-links {
    display: flex;
    gap: 2rem;
    list-style: none;
}

.nav-links a {
    color: var(--text-secondary);
    font-size: 0.95rem;
    font-weight: 500;
    transition: color 0.2s ease;
}

.nav-links a:hover {
    color: var(--text-primary);
}

.nav-toggle {
    display: none;
    flex-direction: column;
    gap: 0.4rem;
    padding: 0.5rem;
}

.nav-toggle span {
    width: 1.5rem;
    height: 2px;
    background: var(--text-primary);
    transition: all 0.3s ease;
}

/* Hero Section */
.hero {
    max-width: 1400px;
    margin: 0 auto;
    padding: 4rem 2rem;
    text-align: center;
}

.hero h1 {
    font-size: 3rem;
    margin-bottom: 0.5rem;
    background: var(--gradient-1);
    -webkit-background-clip: text;
    -webkit-text-fill-color: transparent;
    background-clip: text;
}

.hero .tagline {
    font-size: 1.25rem;
    color: var(--text-secondary);
    margin-bottom: 2rem;
}

.hero-stats {
    display: grid;
    grid-template-columns: repeat(auto-fit, minmax(150px, 1fr));
    gap: 2rem;
    margin-top: 3rem;
    padding-top: 3rem;
    border-top: 1px solid var(--border);
}

.stat {
    text-align: center;
}

.stat-number {
    font-size: 2.5rem;
    font-weight: 700;
    background: var(--gradient-1);
    -webkit-background-clip: text;
    -webkit-text-fill-color: transparent;
    background-clip: text;
}

.stat-label {
    font-size: 0.9rem;
    color: var(--text-secondary);
    margin-top: 0.5rem;
}

/* Search and Filter */
.search-container {
    max-width: 1400px;
    margin: 2rem auto;
    padding: 0 2rem;
}

.search-box {
    width: 100%;
    padding: 1rem;
    background: var(--bg-card);
    border: 1px solid var(--border);
    border-radius: 0.5rem;
    color: var(--text-primary);
    font-size: 1rem;
    margin-bottom: 1.5rem;
}

.search-box::placeholder {
    color: var(--text-muted);
}

.filter-buttons {
    display: flex;
    gap: 1rem;
    flex-wrap: wrap;
    margin-bottom: 2rem;
}

.filter-btn {
    padding: 0.75rem 1.5rem;
    background: var(--bg-card);
    border: 1px solid var(--border);
    border-radius: 0.5rem;
    color: var(--text-secondary);
    cursor: pointer;
    font-weight: 500;
    transition: all 0.2s ease;
}

.filter-btn:hover,
.filter-btn.active {
    background: var(--accent-blue);
    border-color: var(--accent-blue);
    color: white;
}

/* Article Grid */
.article-grid {
    max-width: 1400px;
    margin: 0 auto;
    padding: 0 2rem 4rem 2rem;
    display: grid;
    grid-template-columns: repeat(auto-fill, minmax(350px, 1fr));
    gap: 2rem;
}

.article-card {
    background: var(--bg-card);
    border: 1px solid var(--border);
    border-radius: 0.5rem;
    padding: 1.5rem;
    transition: all 0.3s ease;
    display: flex;
    flex-direction: column;
    cursor: pointer;
}

.article-card:hover {
    background: var(--bg-card-hover);
    border-color: var(--accent-blue);
    transform: translateY(-2px);
}

.card-meta {
    display: flex;
    justify-content: space-between;
    align-items: center;
    margin-bottom: 1rem;
    flex-wrap: wrap;
    gap: 0.5rem;
}

.card-badge {
    display: inline-flex;
    align-items: center;
    gap: 0.35rem;
    padding: 0.35rem 0.75rem;
    background: rgba(59, 130, 246, 0.15);
    border-radius: 0.25rem;
    font-size: 0.75rem;
    font-weight: 600;
    text-transform: uppercase;
    letter-spacing: 0.5px;
}

.badge-countries {
    background: rgba(59, 130, 246, 0.15);
    color: #3b82f6;
}

.badge-companies {
    background: rgba(139, 92, 246, 0.15);
    color: #8b5cf6;
}

.badge-sectors {
    background: rgba(245, 158, 11, 0.15);
    color: #f59e0b;
}

.badge-actions {
    background: rgba(16, 185, 129, 0.15);
    color: #10b981;
}

.badge-guides {
    background: rgba(6, 182, 212, 0.15);
    color: #06b6d4;
}

.badge-data {
    background: rgba(239, 68, 68, 0.15);
    color: #ef4444;
}

.card-audience {
    display: inline-flex;
    align-items: center;
    gap: 0.35rem;
    padding: 0.35rem 0.75rem;
    background: rgba(148, 148, 168, 0.15);
    border-radius: 0.25rem;
    font-size: 0.75rem;
    font-weight: 600;
    color: var(--text-secondary);
}

.card-title {
    font-size: 1.25rem;
    font-weight: 600;
    color: var(--text-primary);
    margin-bottom: 0.75rem;
    line-height: 1.3;
    flex-grow: 1;
}

.card-excerpt {
    font-size: 0.95rem;
    color: var(--text-secondary);
    margin-bottom: 1rem;
    line-height: 1.5;
}

.card-footer {
    display: flex;
    justify-content: space-between;
    align-items: center;
    padding-top: 1rem;
    border-top: 1px solid var(--border);
    color: var(--text-muted);
    font-size: 0.9rem;
}

.read-time {
    display: flex;
    align-items: center;
    gap: 0.35rem;
}

/* Entity Cards (Browse Pages) */
.entity-grid {
    max-width: 1400px;
    margin: 0 auto;
    padding: 0 2rem 4rem 2rem;
    display: grid;
    grid-template-columns: repeat(auto-fill, minmax(300px, 1fr));
    gap: 2rem;
}

.entity-card {
    background: var(--bg-card);
    border: 1px solid var(--border);
    border-radius: 0.5rem;
    padding: 2rem;
    text-align: center;
    transition: all 0.3s ease;
}

.entity-card:hover {
    background: var(--bg-card-hover);
    border-color: var(--accent-blue);
    transform: translateY(-2px);
}

.entity-icon {
    font-size: 3rem;
    margin-bottom: 1rem;
}

.entity-card h3 {
    font-size: 1.5rem;
    color: var(--text-primary);
    margin-bottom: 0.5rem;
}

.entity-card p {
    color: var(--text-secondary);
    margin-bottom: 1.5rem;
    font-size: 0.95rem;
}

.entity-card a {
    display: inline-block;
    padding: 0.75rem 1.5rem;
    background: var(--accent-blue);
    color: white;
    border-radius: 0.25rem;
    font-weight: 600;
    transition: all 0.2s ease;
}

.entity-card a:hover {
    background: var(--accent-purple);
}

/* Entity Landing Page */
.entity-landing {
    max-width: 1400px;
    margin: 0 auto;
    padding: 0 2rem;
}

.entity-hero-section {
    padding: 3rem 0 2rem 0;
    border-bottom: 1px solid var(--border);
    margin-bottom: 2rem;
}

.entity-hero-content {
    display: flex;
    align-items: center;
    gap: 2rem;
}

.entity-hero-icon {
    font-size: 4rem;
}

.entity-hero-title {
    font-size: 2.5rem;
    margin-bottom: 0.5rem;
    background: var(--gradient-1);
    -webkit-background-clip: text;
    -webkit-text-fill-color: transparent;
    background-clip: text;
}

.entity-hero-section p {
    color: var(--text-secondary);
    font-size: 1.1rem;
}

/* Active nav item */
.nav-links a.nav-active {
    color: var(--accent-blue);
}

/* Clickable entity card */
.entity-card {
    cursor: pointer;
}

/* Article Page */
.article-page {
    max-width: 900px;
    margin: 0 auto;
    padding: 2rem;
}

.breadcrumb {
    display: flex;
    gap: 0.5rem;
    margin-bottom: 2rem;
    font-size: 0.9rem;
    color: var(--text-secondary);
    flex-wrap: wrap;
}

.breadcrumb a {
    color: var(--accent-blue);
}

.breadcrumb a:hover {
    color: var(--accent-purple);
}

.breadcrumb span {
    margin: 0 0.5rem;
}

.article-header {
    margin-bottom: 2rem;
}

.article-meta-bar {
    display: flex;
    justify-content: space-between;
    align-items: center;
    margin-bottom: 2rem;
    padding-bottom: 1.5rem;
    border-bottom: 1px solid var(--border);
    flex-wrap: wrap;
    gap: 1rem;
}

.article-category {
    display: flex;
    gap: 0.75rem;
    align-items: center;
}

.entity-name-display {
    font-size: 1.3rem;
    font-weight: 600;
    color: var(--text-primary);
    margin-bottom: 1.5rem;
    padding-bottom: 1rem;
    border-bottom: 1px solid var(--border);
}

/* Sibling Navigation */
.sibling-nav {
    margin-bottom: 2rem;
    padding-bottom: 1.5rem;
    border-bottom: 1px solid var(--border);
}

.sibling-nav-label {
    font-size: 0.95rem;
    font-weight: 600;
    color: var(--text-secondary);
    margin-bottom: 1rem;
}

.sibling-pills {
    display: flex;
    gap: 0.75rem;
    flex-wrap: wrap;
}

.sibling-pill {
    display: inline-flex;
    align-items: center;
    justify-content: center;
    padding: 0.6rem 1.2rem;
    background: var(--bg-card);
    border: 1px solid var(--border);
    border-radius: 2rem;
    color: var(--text-secondary);
    font-size: 0.9rem;
    font-weight: 500;
    transition: all 0.2s ease;
    white-space: nowrap;
    cursor: pointer;
}

.sibling-pill a {
    color: inherit;
    text-decoration: none;
}

.sibling-pill:hover {
    border-color: var(--accent-blue);
    color: var(--accent-blue);
}

.sibling-pill.active {
    background: var(--accent-blue);
    border-color: var(--accent-blue);
    color: white;
}

.sibling-pill.active a {
    color: white;
}

/* Share Bar */
.share-bar {
    display: flex;
    gap: 1rem;
    align-items: center;
    margin-bottom: 2rem;
    padding: 1.5rem;
    background: var(--bg-card);
    border: 1px solid var(--border);
    border-radius: 0.5rem;
    flex-wrap: wrap;
}

.share-bar-label {
    font-size: 0.9rem;
    font-weight: 600;
    color: var(--text-secondary);
    margin-right: 0.5rem;
}

.share-btn {
    display: inline-flex;
    align-items: center;
    justify-content: center;
    padding: 0.7rem 1.2rem;
    background: var(--bg-secondary);
    border: 1px solid var(--border);
    border-radius: 0.4rem;
    color: var(--text-secondary);
    font-size: 0.9rem;
    font-weight: 500;
    cursor: pointer;
    transition: all 0.2s ease;
    white-space: nowrap;
}

.share-btn:hover {
    background: var(--accent-blue);
    border-color: var(--accent-blue);
    color: white;
}

.share-btn.copied {
    background: var(--accent-green);
    border-color: var(--accent-green);
    color: white;
}

.article-content {
    font-size: 1.05rem;
    line-height: 1.8;
    color: var(--text-primary);
}

.article-content h1 {
    font-size: 2.5rem;
    margin-bottom: 1.5rem;
    line-height: 1.2;
    margin-top: 2rem;
}

.article-content h1:first-child {
    margin-top: 0;
}

.article-content h2 {
    font-size: 2rem;
    margin-top: 2rem;
    margin-bottom: 1rem;
    border-bottom: 1px solid var(--border);
    padding-bottom: 0.5rem;
}

.article-content h3 {
    font-size: 1.5rem;
    margin-top: 1.5rem;
    margin-bottom: 0.75rem;
}

.article-content p {
    margin-bottom: 1.25rem;
}

.article-content ul,
.article-content ol {
    margin-left: 2rem;
    margin-bottom: 1.25rem;
}

.article-content li {
    margin-bottom: 0.5rem;
}

.article-content table {
    width: 100%;
    border-collapse: collapse;
    margin-bottom: 1.25rem;
    border: 1px solid var(--border);
}

.article-content th {
    background: var(--bg-secondary);
    padding: 1rem;
    text-align: left;
    font-weight: 600;
    border: 1px solid var(--border);
}

.article-content td {
    padding: 1rem;
    border: 1px solid var(--border);
}

.article-content blockquote {
    margin-left: 0;
    padding-left: 1.5rem;
    border-left: 3px solid var(--accent-blue);
    color: var(--text-secondary);
    font-style: italic;
    margin-bottom: 1.25rem;
}

.article-content hr {
    border: none;
    height: 1px;
    background: var(--border);
    margin: 2rem 0;
}

.article-content code {
    background: var(--bg-card);
    padding: 0.25rem 0.5rem;
    border-radius: 0.25rem;
    font-family: "Courier New", monospace;
    font-size: 0.9em;
    color: var(--accent-cyan);
}

.article-content pre {
    background: var(--bg-card);
    padding: 1.5rem;
    border-radius: 0.5rem;
    overflow-x: auto;
    margin-bottom: 1.25rem;
    border: 1px solid var(--border);
}

.article-content pre code {
    background: none;
    padding: 0;
    color: var(--text-primary);
}

/* More in Category */
.more-in-category {
    margin-top: 4rem;
    padding-top: 2rem;
    border-top: 1px solid var(--border);
}

.more-in-category h3 {
    font-size: 1.5rem;
    margin-bottom: 2rem;
}

.more-grid {
    display: grid;
    grid-template-columns: repeat(auto-fit, minmax(300px, 1fr));
    gap: 2rem;
}

.more-card {
    background: var(--bg-card);
    border: 1px solid var(--border);
    border-radius: 0.5rem;
    padding: 1.5rem;
    transition: all 0.3s ease;
}

.more-card:hover {
    background: var(--bg-card-hover);
    border-color: var(--accent-blue);
}

.more-card h4 {
    font-size: 1.1rem;
    margin-bottom: 0.5rem;
    color: var(--text-primary);
}

.more-card p {
    font-size: 0.9rem;
    color: var(--text-secondary);
    margin-bottom: 1rem;
}

.more-card a {
    font-weight: 600;
}

/* Footer */
.site-footer {
    background: var(--bg-secondary);
    border-top: 1px solid var(--border);
    padding: 3rem 2rem;
    margin-top: 4rem;
}

.footer-content {
    max-width: 1400px;
    margin: 0 auto;
}

.footer-disclaimer {
    color: var(--text-secondary);
    font-size: 0.9rem;
    margin-bottom: 1.5rem;
}

.footer-links {
    display: flex;
    gap: 2rem;
    flex-wrap: wrap;
    margin-bottom: 1.5rem;
}

.footer-links a {
    color: var(--text-secondary);
    font-size: 0.9rem;
}

.footer-links a:hover {
    color: var(--text-primary);
}

.back-to-top {
    display: none;
    position: fixed;
    bottom: 2rem;
    right: 2rem;
    width: 3rem;
    height: 3rem;
    background: var(--accent-blue);
    border-radius: 50%;
    color: white;
    align-items: center;
    justify-content: center;
    cursor: pointer;
    z-index: 999;
    transition: all 0.3s ease;
}

.back-to-top:hover {
    background: var(--accent-purple);
    transform: translateY(-2px);
}

.back-to-top.visible {
    display: flex;
}

/* Feedback Widget */
.feedback-widget {
    position: fixed;
    bottom: 2rem;
    left: 2rem;
    z-index: 1000;
}
.feedback-toggle {
    background: var(--accent-blue);
    color: white;
    border: none;
    padding: 0.6rem 1.2rem;
    border-radius: 2rem;
    cursor: pointer;
    font-size: 0.9rem;
    font-weight: 600;
    box-shadow: 0 4px 15px rgba(59,130,246,0.4);
    transition: all 0.3s ease;
}
.feedback-toggle:hover {
    background: var(--accent-purple);
    transform: translateY(-2px);
}
.feedback-panel {
    display: none;
    position: absolute;
    bottom: 3.5rem;
    left: 0;
    width: 340px;
    background: var(--surface);
    border: 1px solid var(--border);
    border-radius: 1rem;
    box-shadow: 0 10px 40px rgba(0,0,0,0.3);
    overflow: hidden;
}
.feedback-panel.open {
    display: block;
    animation: feedbackSlideUp 0.25s ease;
}
@keyframes feedbackSlideUp {
    from { opacity: 0; transform: translateY(10px); }
    to { opacity: 1; transform: translateY(0); }
}
.feedback-header {
    display: flex;
    justify-content: space-between;
    align-items: center;
    padding: 1rem 1.2rem;
    border-bottom: 1px solid var(--border);
}
.feedback-header h3 {
    margin: 0;
    font-size: 1rem;
    color: var(--text-primary);
}
.feedback-close {
    background: none;
    border: none;
    color: var(--text-muted);
    cursor: pointer;
    font-size: 1.2rem;
    padding: 0;
}
.feedback-form {
    padding: 1rem 1.2rem;
}
.feedback-field {
    margin-bottom: 0.8rem;
}
.feedback-field label {
    display: block;
    font-size: 0.8rem;
    color: var(--text-secondary);
    margin-bottom: 0.3rem;
    font-weight: 600;
}
.feedback-type-btns {
    display: flex;
    gap: 0.5rem;
}
.feedback-type-label {
    display: flex !important;
    align-items: center;
    gap: 0.25rem;
    font-size: 0.8rem !important;
    color: var(--text-primary) !important;
    cursor: pointer;
    padding: 0.3rem 0.6rem;
    border: 1px solid var(--border);
    border-radius: 0.5rem;
    transition: all 0.2s;
}
.feedback-type-label:has(input:checked) {
    border-color: var(--accent-blue);
    background: rgba(59,130,246,0.1);
}
.feedback-type-label input {
    display: none;
}
.feedback-form textarea,
.feedback-form input[type="email"] {
    width: 100%;
    padding: 0.5rem 0.7rem;
    background: var(--background);
    border: 1px solid var(--border);
    border-radius: 0.5rem;
    color: var(--text-primary);
    font-size: 0.85rem;
    font-family: inherit;
    resize: vertical;
    box-sizing: border-box;
}
.feedback-form textarea:focus,
.feedback-form input[type="email"]:focus {
    outline: none;
    border-color: var(--accent-blue);
}
.feedback-submit {
    width: 100%;
    background: var(--accent-blue);
    color: white;
    border: none;
    padding: 0.6rem;
    border-radius: 0.5rem;
    cursor: pointer;
    font-weight: 600;
    font-size: 0.9rem;
    transition: background 0.2s;
}
.feedback-submit:hover {
    background: var(--accent-purple);
}
.feedback-success {
    padding: 2rem;
    text-align: center;
    color: var(--text-secondary);
}

/* Pagination */
.pagination {
    display: flex;
    justify-content: center;
    gap: 0.5rem;
    margin: 3rem 0;
}

.pagination a,
.pagination span {
    padding: 0.75rem 1rem;
    background: var(--bg-card);
    border: 1px solid var(--border);
    border-radius: 0.25rem;
    color: var(--text-secondary);
    transition: all 0.2s ease;
}

.pagination a:hover {
    background: var(--accent-blue);
    border-color: var(--accent-blue);
    color: white;
}

.pagination span.current {
    background: var(--accent-blue);
    border-color: var(--accent-blue);
    color: white;
}

/* Responsive */
@media (max-width: 768px) {
    .header-inner {
        padding: 1rem;
    }

    .nav-links {
        display: none;
        position: absolute;
        top: 4rem;
        left: 0;
        right: 0;
        background: var(--bg-secondary);
        flex-direction: column;
        gap: 0;
        border-bottom: 1px solid var(--border);
        border-radius: 0;
    }

    .nav-links.active {
        display: flex;
    }

    .nav-links li {
        padding: 1rem;
        border-bottom: 1px solid var(--border);
    }

    .nav-toggle {
        display: flex;
    }

    .hero h1 {
        font-size: 2rem;
    }

    .hero .tagline {
        font-size: 1rem;
    }

    .article-grid {
        grid-template-columns: 1fr;
        padding: 0 1rem 2rem 1rem;
    }

    .entity-grid {
        grid-template-columns: 1fr;
        padding: 0 1rem 2rem 1rem;
    }

    .article-page {
        padding: 1rem;
    }

    .article-content h1 {
        font-size: 1.75rem;
    }

    .article-content h2 {
        font-size: 1.5rem;
    }

    .article-meta-bar {
        flex-direction: column;
        align-items: flex-start;
    }

    .search-container {
        padding: 0 1rem;
    }

    .filter-buttons {
        overflow-x: auto;
        padding-bottom: 1rem;
    }

    .share-bar {
        flex-direction: column;
        align-items: flex-start;
    }

    .sibling-pills {
        overflow-x: auto;
        padding-bottom: 0.5rem;
    }

    .entity-hero-content {
        flex-direction: column;
        text-align: center;
    }

    .entity-hero-title {
        font-size: 2rem;
    }
}

@media (max-width: 480px) {
    .header-inner {
        padding: 0.75rem;
    }

    .site-logo {
        font-size: 1.2rem;
    }

    .hero h1 {
        font-size: 1.5rem;
    }

    .hero-stats {
        grid-template-columns: 1fr;
    }

    .article-grid {
        gap: 1rem;
    }

    .article-content {
        font-size: 1rem;
    }

    .article-content h1 {
        font-size: 1.5rem;
    }

    .article-content h2 {
        font-size: 1.25rem;
    }

    .article-content h3 {
        font-size: 1.1rem;
    }

    .card-title {
        font-size: 1rem;
    }

    .breadcrumb {
        font-size: 0.8rem;
    }

    .sibling-pill {
        padding: 0.5rem 1rem;
        font-size: 0.85rem;
    }

    .share-btn {
        padding: 0.6rem 1rem;
        font-size: 0.85rem;
    }
}

/* PHASE D1: Newsletter CTA */
.newsletter-cta {
    background: var(--bg-card);
    border: 1px solid var(--border);
    border-radius: 0.5rem;
    padding: 2.5rem;
    text-align: center;
    margin: 3rem 0;
    max-width: 600px;
    margin-left: auto;
    margin-right: auto;
}

.newsletter-cta h3 {
    font-size: 1.5rem;
    margin-bottom: 0.5rem;
    color: var(--text-primary);
}

.newsletter-cta p {
    color: var(--text-secondary);
    margin-bottom: 1.5rem;
    font-size: 1rem;
}

.newsletter-cta form {
    display: flex;
    gap: 0.5rem;
    flex-direction: column;
}

.newsletter-cta input {
    padding: 0.75rem 1rem;
    background: var(--bg-primary);
    border: 1px solid var(--border);
    border-radius: 0.25rem;
    color: var(--text-primary);
    font-size: 1rem;
}

.newsletter-cta input::placeholder {
    color: var(--text-muted);
}

.newsletter-cta button {
    padding: 0.75rem 1.5rem;
    background: var(--accent-blue);
    color: white;
    border: none;
    border-radius: 0.25rem;
    font-weight: 600;
    cursor: pointer;
    transition: background 0.2s ease;
}

.newsletter-cta button:hover {
    background: var(--accent-purple);
}

/* PHASE F1: Feedback bar */
.feedback-bar {
    display: flex;
    gap: 2rem;
    justify-content: center;
    padding: 2rem 0;
    border-top: 1px solid var(--border);
    margin-top: 3rem;
    flex-wrap: wrap;
}

.feedback-bar a {
    color: var(--text-secondary);
    font-weight: 500;
    transition: color 0.2s ease;
    display: inline-flex;
    align-items: center;
    gap: 0.5rem;
}

.feedback-bar a:hover {
    color: var(--accent-blue);
}

/* PHASE C1: Company view toggles */
.view-toggle-buttons {
    display: flex;
    gap: 1rem;
    justify-content: center;
    margin: 2rem 0;
    flex-wrap: wrap;
}

.view-toggle-btn {
    padding: 0.75rem 1.5rem;
    background: var(--bg-card);
    border: 1px solid var(--border);
    border-radius: 0.25rem;
    color: var(--text-secondary);
    font-weight: 500;
    cursor: pointer;
    transition: all 0.2s ease;
}

.view-toggle-btn.active {
    background: var(--accent-blue);
    color: white;
    border-color: var(--accent-blue);
}

.view-toggle-btn:hover {
    border-color: var(--accent-blue);
    color: var(--text-primary);
}

.entity-view {
    display: none;
}

.entity-view.active {
    display: block;
}

.sector-group {
    margin-bottom: 3rem;
}

.sector-group h3 {
    font-size: 1.25rem;
    margin-bottom: 1.5rem;
    color: var(--text-primary);
    padding-bottom: 0.5rem;
    border-bottom: 1px solid var(--border);
}

.country-group {
    margin-bottom: 3rem;
}

.country-group h3 {
    font-size: 1.25rem;
    margin-bottom: 1.5rem;
    color: var(--text-primary);
    padding-bottom: 0.5rem;
    border-bottom: 1px solid var(--border);
}

/* Related section for companies */
.related-section {
    background: var(--bg-card);
    border: 1px solid var(--border);
    border-radius: 0.5rem;
    padding: 2rem;
    margin: 3rem 0;
}

.related-section h3 {
    font-size: 1.25rem;
    margin-bottom: 1.5rem;
    color: var(--text-primary);
}

.related-links {
    display: flex;
    flex-direction: column;
    gap: 1rem;
}

.related-links a {
    padding: 1rem;
    background: var(--bg-primary);
    border-radius: 0.25rem;
    color: var(--accent-blue);
    font-weight: 500;
    transition: all 0.2s ease;
    display: flex;
    justify-content: space-between;
    align-items: center;
}

.related-links a:hover {
    background: var(--bg-card-hover);
    color: var(--accent-purple);
}

@media (max-width: 768px) {
    .newsletter-cta {
        padding: 1.5rem;
    }

    .feedback-bar {
        gap: 1rem;
    }

    .view-toggle-buttons {
        gap: 0.5rem;
    }

    .view-toggle-btn {
        padding: 0.6rem 1rem;
        font-size: 0.9rem;
    }
}
</style>
    <!-- GA4 Analytics -->
    <script async src="https://www.googletagmanager.com/gtag/js?id=G-S9Z93KZ2Z2"></script>
    <script>window.dataLayer=window.dataLayer||[];function gtag(){dataLayer.push(arguments);}gtag('js',new Date());gtag('config','G-S9Z93KZ2Z2');</script>
</head>
<body>
    <header class="site-header">
        <div class="header-inner">
            <a href="/" class="site-logo">
                <div class="logo-mark">30</div>
                <div class="logo-text">
                    <div class="logo-text-main">2030</div>
                    <div class="logo-text-sub">Report</div>
                </div>
            </a>
            <nav class="nav-links">
                <li><a href="/">Dashboard</a></li>
                <li><a href="/browse/countries.html">Countries</a></li>
                <li><a href="/browse/companies.html">Companies</a></li>
                <li><a href="/browse/sectors.html">Sectors</a></li>
                <li><a href="/government.html">Government</a></li>
                <li><a href="/search.html">Search</a></li>
                <li><a href="/about.html">About</a></li>
            </nav>
            <button class="nav-toggle" onclick="toggleNav()">
                <span></span>
                <span></span>
                <span></span>
            </button>
        </div>
    </header>

    <main class="article-page">
        <div class="breadcrumb">
            <a href="/">Home</a><span>/</span><a href="/browse/companies.html">Companies</a><span>/</span><a href="/browse/companies/sanofi.html">Sanofi</a><span>/</span><span>Employee</span>
        </div>

        <article class="article-header">
            <div class="article-meta-bar">
                <div class="article-category">
                    <span class="card-badge badge-companies">üè¢ Companies</span>
                    <span class="card-audience">üë§ Employee</span>
                </div>
                <div class="read-time">‚è±Ô∏è 19 min read</div>
            </div>

            <div class="entity-name-display">üè¢ Sanofi</div>
            
        <div class="share-bar">
            <span class="share-bar-label">Share:</span>
            <button class="share-btn" onclick="copyLink(event)">üìã Copy Link</button>
            <button class="share-btn" onclick="shareOnTwitter()">ùïè Twitter</button>
            <button class="share-btn" onclick="shareOnLinkedIn()">üíº LinkedIn</button>
            <button class="share-btn" onclick="shareOnFacebook()">üìò Facebook</button>
            <button class="share-btn" onclick="shareOnWhatsApp()">üí¨ WhatsApp</button>
            <button class="share-btn" onclick="shareViaEmail()">‚úâÔ∏è Email</button>
        </div>
        
            
        <div class="sibling-nav">
            <div class="sibling-nav-label">All Perspectives:</div>
            <div class="sibling-pills">
                <div class="sibling-pill "><a href="/articles/companies-europe-sanofi-sanofi-ceo.html">CEO</a></div><div class="sibling-pill active"><a href="/articles/companies-europe-sanofi-sanofi-employee.html">Employee</a></div><div class="sibling-pill "><a href="/articles/companies-europe-sanofi-sanofi-investor.html">Analyst</a></div>
            </div>
        </div>
        

            <div class="article-content">
                <h1>SANOFI SA: TRANSFORMATION FROM PHARMA CONSOLIDATOR TO SPECIALTY-VACCINES LEADER</h1>
<h2>A Macro Intelligence Memo | June 2030 | Employee Edition</h2>
<hr />
<p><strong>FROM:</strong> The 2030 Report, Macro Intelligence Unit<br />
<strong>TO:</strong> Sanofi Employees, All Levels<br />
<strong>RE:</strong> Organizational Transformation, Portfolio Evolution, Workforce Repositioning, and Career Implications<br />
<strong>DATE:</strong> June 2030<br />
<strong>CLASSIFICATION:</strong> Employee Intelligence | Open Distribution</p>
<hr />
<h2>EXECUTIVE SUMMARY</h2>
<p>Sanofi has undergone fundamental strategic transformation (2025-2030) from a "consolidator pharma" model (defensive portfolio, M&amp;A-driven growth) to a "specialty-vaccines growth company" model (high-margin specialty care, breakbuster vaccines, AI-integrated drug discovery). This transformation has created a two-speed workforce: growth businesses (vaccines, specialty immunology, computational drug discovery) expanding headcount and compensation at 8-12% annually, and declining businesses (generics, legacy primary care) contracting at 6-10% annually.</p>
<p>The macroeconomic driver is bifurcation in pharmaceutical markets: specialty care drugs (immunology, oncology, rare diseases) command 40-60% gross margins and 12-18% annual price appreciation, while generics face 15-25% annual price compression. Sanofi's portfolio shift‚Äîreducing generics from 18% of revenue (2025) to 8% of revenue (2030), while expanding vaccines and specialty care from 48% to 68%‚Äîcreates 620 net new permanent positions in high-margin businesses and requires 280 workforce reductions in declining generics portfolio.</p>
<p>For Sanofi employees, this creates three distinct career ecosystems: (1) specialty-vaccines growth businesses offering 8-12% annual compensation growth and accelerated advancement; (2) declining generics portfolio with 1-3% compensation growth and limited advancement; (3) corporate support functions with 3-5% compensation growth, largely uncorrelated with business portfolio performance.</p>
<p>The critical inflection point: June 2030 represents peak hiring velocity for vaccines and specialty care (540 net new positions across both portfolios in FY2030), with deceleration expected post-2032 as pipeline matures and manufacturing capacity fully scales.</p>
<hr />
<h2>SECTION 1: PORTFOLIO EVOLUTION &amp; FINANCIAL DYNAMICS</h2>
<h3>Vaccine Business: RSV Blockbuster &amp; Dengue Pipeline</h3>
<p><strong>Historical context (2025):</strong> Sanofi's vaccine portfolio was mature but declining. RSV vaccine (initially approved 2023 for elderly population) had generated ‚Ç¨380M in FY2025 revenue, with limited expansion potential. Dengue vaccine (Dengvaxia) was managing reputational risk post-2017 Philippine controversy.</p>
<p><strong>FY2030 Performance (Actual):</strong></p>
<ul>
<li><strong>RSV vaccine revenue:</strong> ‚Ç¨4.8 billion (1,160% growth 2025-2030), now 14.2% of Sanofi's ‚Ç¨33.8B total revenue</li>
<li><strong>RSV manufacturing capacity:</strong> Three commercial-scale manufacturing facilities (Amherst MA, Marcy NY, Neuville-sur-Oise FR), producing 120 million doses annually</li>
<li><strong>RSV market share:</strong> 35% of global RSV-eligible population (age 60+), competing against GSK (Arexvy, 28% share) and Moderna/Merck (RSV partnership, 18% share)</li>
<li><strong>Gross margin:</strong> 78% (RSV vaccine), highest-margin vaccine offering globally</li>
<li><strong>Customer base:</strong> 145 countries with government reimbursement contracts (60% of addressable market)</li>
</ul>
<p><strong>Dengue vaccine growth:</strong><br />
- FY2030 revenue: ‚Ç¨1.2B (vs. ‚Ç¨420M in 2025), driven by expanded age indications (now approved 2-45 years in 28 countries) and geographic expansion to dengue-endemic regions<br />
- Manufacturing constraint: Only one manufacturing facility (Vero cell platform); capacity expansion deferred pending RSV demand clarity</p>
<p><strong>Strategic importance:</strong> RSV vaccine success has become primary EBITDA driver, generating ‚Ç¨3.7B incremental EBITDA annually (post-COGS, SG&amp;A) versus 2025 baseline. CEO Marc Lachenauer (and successor Paul Hudson successor, effective Jan 2030) has positioned RSV as "anchor" business providing cash flow for specialty care M&amp;A and AI drug discovery investment.</p>
<h3>Specialty Care: Dupilumab Maturation &amp; Oncology Acceleration</h3>
<p><strong>Dupilumab performance (2030):</strong><br />
- <strong>Revenue:</strong> ‚Ç¨4.1B annually (peak sales, FY2030), down from ‚Ç¨4.3B guidance as market saturation in atopic dermatitis approaches<br />
- <strong>Patient population:</strong> 1.2M patients globally (vs. 680k in 2025), with 2-3% annual growth now replacing market expansion with patient stickiness<br />
- <strong>Pricing:</strong> Maintained 7-9% annual price increases 2025-2030, driving revenue growth despite patient count growth deceleration<br />
- <strong>Indication expansion:</strong> Label expanded to include chronic spontaneous urticaria (CSU) and eosinophilic disease, offsetting market maturation in primary indication (atopic dermatitis)</p>
<p><strong>Sanofi Oncology portfolio growth:</strong><br />
- <strong>Revenue (2030):</strong> ‚Ç¨6.2B annually, vs. ‚Ç¨3.8B in 2025 (63% growth)<br />
- <strong>Key assets:</strong> Sarclisa (anti-BCMA monoclonal antibody, multiple myeloma, ‚Ç¨1.8B), Tolima (anti-CD38 bispecific, ‚Ç¨2.1B), next-generation BTK/EGFR inhibitor (ex-Synthorx acquisition, FDA approved 2029, ‚Ç¨800M 2030 run rate)<br />
- <strong>AI-driven development:</strong> Tolima was discovered using AI-assisted target identification (Exscientia partnership), reducing development timeline by 2-3 years versus traditional approach<br />
- <strong>Growth trajectory:</strong> Oncology revenue targeted to reach ‚Ç¨8.5-9.2B by 2033, driven by Tolima label expansion (now approved for CLL, small cell lung cancer) and next-generation pipeline candidates</p>
<p><strong>Immunology (non-Dupilumab) growth:</strong><br />
- Revenue ‚Ç¨2.1B (FY2030), driven by JAK inhibitors, complement inhibitors (Iptacopan for autoimmune hemolytic anemia, C5a pathway targeting), and checkpoint modulators<br />
- Growth rate: 12-15% annually, faster than company average</p>
<p><strong>Specialty care aggregate:</strong> ‚Ç¨12.4B revenue (2030), 37% of total revenue, growing 8-12% annually</p>
<h3>Generics Portfolio: Managed Decline</h3>
<p><strong>Historical role:</strong> Generics portfolio (primarily manufactured in India, France, and Brazil) generated ‚Ç¨7.2B revenue (2025), 25% of total. Provides cash flow and scale benefits to manufacturing infrastructure.</p>
<p><strong>FY2030 performance:</strong><br />
- <strong>Revenue:</strong> ‚Ç¨2.8B (61% decline from 2025), driven by:<br />
  - Divestitures of non-strategic generics in Japan (-‚Ç¨1.8B), India (-‚Ç¨800M), Brazil (-‚Ç¨600M)<br />
  - Price compression in European generics markets (15-18% annual price decline driven by biosimilar competition, health authority cost pressures)<br />
  - Market share losses in US generic market to low-cost generic manufacturers (Teva, Sandoz, Sun Pharma)</p>
<ul>
<li><strong>Gross margin:</strong> 28-32% (vs. 38% in 2025), as manufacturing optimization fails to offset price compression</li>
<li><strong>Operating margin:</strong> 8-12% (vs. 18% in 2025), reflecting minimal SG&amp;A reduction relative to revenue decline</li>
</ul>
<p><strong>Strategic rationale for exit:</strong> Generics provide &lt;2% company EBITDA contribution post-margin compression; manufacturing footprint (28 facilities globally) consumes disproportionate supply chain management overhead. Divestitures to Indian companies (Cipla, Dr. Reddy's) and Brazilian companies (EMS) reduced this overhead by ~‚Ç¨200-280M annually.</p>
<p><strong>Transition timeline:</strong> Generics portfolio reduction expected to complete by 2032 (residual: ‚Ç¨800-1.0B revenue, primarily niche injectables, oncology supportive care). Workforce reduction: 1,640 FTE in 2025 ‚Üí 740 FTE by 2032 (-880 positions).</p>
<h3>AI Drug Discovery: Major Strategic Investment</h3>
<p><strong>Investment profile:</strong><br />
- <strong>2025 baseline:</strong> Sanofi R&amp;D budget allocation to AI/ML: ‚Ç¨160M/year (3.2% of R&amp;D)<br />
- <strong>2030 allocation:</strong> ‚Ç¨680M/year (9.8% of R&amp;D), representing 3.2x cumulative investment increase<br />
- <strong>Partnerships:</strong> Exscientia (discovered Tolima, continuing drug design partnership), DeepMind Pharma (protein structure prediction, target validation), Recursion Pharmaceuticals (cell biology models), alongside internal Sanofi Ventures/R&amp;D collaborations</p>
<p><strong>Pipeline impact:</strong><br />
- <strong>AI-discovered candidates in clinical development:</strong> 8 programs (as of June 2030), up from 1 in 2025<br />
- <strong>Expected development acceleration:</strong> AI-identified targets reduce candidate selection time from 3-4 years to 12-18 months, and improve clinical success rates by estimated 15-25% (vs. historical 8-12% Phase 2 success rates for new targets)<br />
- <strong>Time-to-market benefit:</strong> Tolima (AI-discovered, approved 2029) represented 3-year development acceleration vs. historical timelines, delivering ‚Ç¨2.1B in FY2030 revenue 3 years earlier than traditional drug discovery would project</p>
<p><strong>Competitive context:</strong> Sanofi is attempting to catch up with Roche (invested ‚Ç¨1.2B in AI drug discovery since 2024, partnering with Exscientia, DeepMind, Google Quantum AI) and GSK (acquired Isomorphic Labs stake, established AI-led oncology pipeline). Sanofi's relative position: 6-12 months behind in capability, but leveraging partnership strategy to accelerate.</p>
<hr />
<h2>SECTION 2: WORKFORCE STRUCTURE &amp; COMPENSATION TRANSFORMATION</h2>
<h3>Vaccines Division</h3>
<p><strong>Headcount evolution:</strong></p>
<table>
<thead>
<tr>
<th>Role Category</th>
<th>FY2025</th>
<th>FY2030</th>
<th>Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vaccine manufacturing</td>
<td>1,240</td>
<td>2,140</td>
<td>+72%</td>
</tr>
<tr>
<td>Vaccine clinical research</td>
<td>680</td>
<td>1,480</td>
<td>+118%</td>
</tr>
<tr>
<td>Commercial/medical affairs</td>
<td>420</td>
<td>840</td>
<td>+100%</td>
</tr>
<tr>
<td>Regulatory/quality assurance</td>
<td>380</td>
<td>620</td>
<td>+63%</td>
</tr>
<tr>
<td><strong>Vaccines Total</strong></td>
<td><strong>2,720</strong></td>
<td><strong>5,080</strong></td>
<td><strong>+87%</strong></td>
</tr>
</tbody>
</table>
<p><strong>RSV vaccine explosion driver:</strong> RSV manufacturing capacity expansion (2 additional facilities commissioned 2028-2029) required 880 manufacturing personnel. Clinical development for next-generation RSV (recombinant RSV expressing modified surface proteins, targeting pediatric population) required 340 clinical research positions. Commercial expansion to 145 countries required 420 medical affairs positions.</p>
<p><strong>Compensation structure (June 2030):</strong></p>
<ul>
<li><strong>Manufacturing technicians:</strong> ‚Ç¨52-68k base (2025: ‚Ç¨48-58k), +8-17% growth; shift premiums +‚Ç¨8-12k/year</li>
<li><strong>Manufacturing engineers:</strong> ‚Ç¨78-98k base (2025: ‚Ç¨70-88k), +11-14% growth</li>
<li><strong>Clinical research associates:</strong> ‚Ç¨58-72k base (2025: ‚Ç¨52-64k), +11-13% growth; advanced degree premium +‚Ç¨8-15k/year</li>
<li><strong>Senior clinical scientists:</strong> ‚Ç¨98-128k base (2025: ‚Ç¨88-115k), +11-13% growth; bonus structure 15-25% (vs. 10-15% historical)</li>
<li><strong>Medical affairs managers:</strong> ‚Ç¨72-92k base (2025: ‚Ç¨65-82k), +11-15% growth; international assignment allowances ‚Ç¨8-12k/year</li>
</ul>
<p><strong>Advancement velocity:</strong> Vaccines division experiencing compressed promotion timelines. Manufacturing supervisor promotions occurring at 4-5 year tenure (vs. 7-8 year historical); clinical research manager promotions at 5-6 year tenure (vs. 8-10 year historical).</p>
<h3>Specialty Care Division</h3>
<p><strong>Headcount evolution:</strong></p>
<table>
<thead>
<tr>
<th>Role Category</th>
<th>FY2025</th>
<th>FY2030</th>
<th>Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical development</td>
<td>1,840</td>
<td>2,560</td>
<td>+39%</td>
</tr>
<tr>
<td>Commercial/oncology sales</td>
<td>1,200</td>
<td>1,680</td>
<td>+40%</td>
</tr>
<tr>
<td>Regulatory affairs</td>
<td>420</td>
<td>540</td>
<td>+29%</td>
</tr>
<tr>
<td>Safety/medical surveillance</td>
<td>380</td>
<td>520</td>
<td>+37%</td>
</tr>
<tr>
<td><strong>Specialty Care Total</strong></td>
<td><strong>3,840</strong></td>
<td><strong>5,300</strong></td>
<td><strong>+38%</strong></td>
</tr>
</tbody>
</table>
<p><strong>Expansion driver:</strong> Oncology pipeline acceleration (Tolima label expansion, next-generation pipeline) and specialty immunology growth (rare disease expansion) drove clinical development headcount growth of 34%. Oncology sales force expansion (33% increase in field-based oncology specialists).</p>
<p><strong>Compensation structure (June 2030):</strong></p>
<ul>
<li><strong>Clinical research coordinator:</strong> ‚Ç¨48-62k base (2025: ‚Ç¨44-56k), +9-11% growth</li>
<li><strong>Senior clinical scientist/study lead:</strong> ‚Ç¨92-118k base (2025: ‚Ç¨82-108k), +12-10% growth; performance bonus 18-22% (vs. 14-18% historical)</li>
<li><strong>Oncology specialist (field sales):</strong> ‚Ç¨68-88k base (2025: ‚Ç¨60-78k), +13-13% growth; commission structure 20-30% of base (increased from 15-25%)</li>
<li><strong>Regulatory specialist:</strong> ‚Ç¨78-98k base (2025: ‚Ç¨70-90k), +11-9% growth</li>
</ul>
<p><strong>Advancement velocity:</strong> Specialty care experiencing more modest acceleration than vaccines; promotion timelines compressing 1-2 years (clinical scientist manager at 6-7 year tenure vs. 8-10 year historical).</p>
<h3>AI Drug Discovery Division</h3>
<p><strong>Headcount evolution:</strong></p>
<table>
<thead>
<tr>
<th>Role Category</th>
<th>FY2025</th>
<th>FY2030</th>
<th>Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Computational scientists/chemists</td>
<td>160</td>
<td>840</td>
<td>+425%</td>
</tr>
<tr>
<td>AI/ML engineers</td>
<td>80</td>
<td>340</td>
<td>+325%</td>
</tr>
<tr>
<td>Structural biologists</td>
<td>120</td>
<td>380</td>
<td>+217%</td>
</tr>
<tr>
<td>Project/program management</td>
<td>90</td>
<td>280</td>
<td>+211%</td>
</tr>
<tr>
<td><strong>AI Drug Discovery Total</strong></td>
<td><strong>450</strong></td>
<td><strong>1,840</strong></td>
<td><strong>+309%</strong></td>
</tr>
</tbody>
</table>
<p><strong>Investment shock:</strong> AI drug discovery headcount growth of 310% (2025-2030) represents most aggressive hiring expansion in Sanofi history. Reflects ‚Ç¨520M incremental R&amp;D investment directed to AI capabilities.</p>
<p><strong>Skill scarcity:</strong> Computational chemists, AI/ML specialists, and structural biologists with pharma domain expertise are globally scarce. Sanofi competed against big pharma (Roche, Novo Nordisk, J&amp;J), big tech (Google, Microsoft, OpenAI), and specialized biotech (Exscientia, Recursion) for talent.</p>
<p><strong>Compensation structure (June 2030):</strong></p>
<ul>
<li><strong>Computational scientist (junior PhD):</strong> ‚Ç¨78-98k base (2025: ‚Ç¨68-82k), +15-19% growth; performance bonus 12-18%; annual equity grants ‚Ç¨5-8k (new benefit, introduced 2028)</li>
<li><strong>AI/ML engineer (industry experience):</strong> ‚Ç¨108-138k base (2025: ‚Ç¨85-105k), +27-31% growth; performance bonus 18-25%; annual equity grants ‚Ç¨8-12k</li>
<li><strong>Senior computational scientist/architect:</strong> ‚Ç¨148-188k base (2025: ‚Ç¨120-150k), +23-25% growth; performance bonus 25-35%; annual equity grants ‚Ç¨15-20k</li>
<li><strong>AI ML tech lead:</strong> ‚Ç¨178-228k base (2025: ‚Ç¨130-160k), +37-43% growth; performance bonus 30-40%; annual equity grants ‚Ç¨20-28k</li>
</ul>
<p><strong>Compensation premium vs. other divisions:</strong> AI division compensation is 35-55% above specialty care and 45-68% above vaccines division (at equivalent experience level). External market pressures: OpenAI/DeepMind offer ‚Ç¨140-200k for ML engineers; Google ‚Ç¨130-180k; Sanofi's positioning is upper-quartile pay to compete for top-quartile talent.</p>
<p><strong>Advancement velocity:</strong> AI division experiences rapid advancement. ML engineer hired in 2027 (‚Ç¨85k) at 3-year experience level advanced to "senior ML engineer" (‚Ç¨168k) or "tech lead" (‚Ç¨210k) by June 2030‚Äî3-year tenure with 2-2.5x salary uplift, vastly exceeding company norms.</p>
<h3>Generics Division</h3>
<p><strong>Headcount evolution:</strong></p>
<table>
<thead>
<tr>
<th>Role Category</th>
<th>FY2025</th>
<th>FY2030</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manufacturing</td>
<td>1,060</td>
<td>480</td>
<td>-55%</td>
</tr>
<tr>
<td>Quality/regulatory</td>
<td>340</td>
<td>180</td>
<td>-47%</td>
</tr>
<tr>
<td>Supply chain</td>
<td>280</td>
<td>140</td>
<td>-50%</td>
</tr>
<tr>
<td>Commercial</td>
<td>420</td>
<td>180</td>
<td>-57%</td>
</tr>
<tr>
<td><strong>Generics Total</strong></td>
<td><strong>2,100</strong></td>
<td><strong>980</strong></td>
<td><strong>-53%</strong></td>
</tr>
</tbody>
</table>
<p><strong>Divestitures &amp; workforce reduction:</strong> Generics business reduction driven by portfolio exit. Manufacturing headcount declined from 1,060 (FY2025) to 480 (FY2030), primarily through facility closures (Spain facility closed 2027, Brazil facility divested 2028, India operations reduced 60%).</p>
<p><strong>Compensation structure (June 2030):</strong></p>
<ul>
<li><strong>Manufacturing technician:</strong> ‚Ç¨38-48k base (2025: ‚Ç¨36-46k), +2-5% growth (stalled)</li>
<li><strong>Manufacturing engineer:</strong> ‚Ç¨58-72k base (2025: ‚Ç¨56-70k), +2-4% growth (limited)</li>
<li><strong>Quality specialist:</strong> ‚Ç¨52-66k base (2025: ‚Ç¨50-64k), +2-4% growth (stalled)</li>
</ul>
<p><strong>Advancement virtually frozen:</strong> Generics division experienced zero promotions in 2029-2030 (19 positions eliminated through attrition, 0 replacements). Senior roles (plant managers, operations directors) are "held" for retirement buyouts (Sanofi offered ‚Ç¨150-200k buyout packages to 80+ personnel planning 2030-2032 departures).</p>
<p><strong>Attrition characteristics:</strong> Generics division attrition is "push" (dissatisfied departures) rather than "pull" (attractive external opportunities). Exit surveys show declining morale: "I plan to stay at Sanofi" response rate of 28% (vs. 74% in vaccines, 62% in specialty care, 68% in AI discovery).</p>
<hr />
<h2>SECTION 3: STRATEGIC CAREER POSITIONING</h2>
<h3>Tier 1: AI Drug Discovery Division (Strategic Priority)</h3>
<p><strong>Current positioning:</strong> Highest compensation, fastest advancement, strongest external optionality.</p>
<p><strong>Recommended positioning:</strong><br />
1. <strong>Build domain expertise intersection:</strong> Pharma domain knowledge (target biology, drug safety, regulatory pathways) combined with AI/ML methodology creates rare expertise. By 2032, pharma AI domain specialists will command 40-60% premium over non-pharma ML engineers.<br />
2. <strong>Develop program ownership:</strong> Transition from individual contributor (ML engineer) to program lead (owning 1-2 AI-enabled drug discovery programs). Program ownership creates CEO/CTO pathway visibility.<br />
3. <strong>Maximize equity exposure:</strong> Sanofi equity grants to AI division (‚Ç¨5-20k annually) are new benefit; elect to receive in unvested restricted stock rather than cash. Four-year grant value could represent ‚Ç¨20-80k upside if Sanofi stock appreciates 15-20% annually (which is credible given AI drug discovery growth trajectory).</p>
<p><strong>External optionality:</strong> AI ML engineers with 2-3 years pharma experience are highly recruited by OpenAI (pharma-focused agents), Google DeepMind (life sciences), Anthropic (scientific reasoning LLMs), and specialized biotech (Recursion, Exscientia, Benchling). Compensation premium available via external exit: +35-50%.</p>
<p><strong>Optimal tenure:</strong> 3-4 years at Sanofi (through 2032-2033), building program ownership and domain expertise, then transition to CTO/research leader role at AI biotech or big tech pharma team.</p>
<h3>Tier 2: Vaccines Division (Growth Business, Operational Focus)</h3>
<p><strong>Current positioning:</strong> Strong growth, solid compensation, advancement opportunity, but less external prestige than AI.</p>
<p><strong>Recommended positioning:</strong><br />
1. <strong>Develop manufacturing operations expertise:</strong> RSV manufacturing is complex (cell-based Vero platform, cryogenic logistics, scale-up challenges). Expertise in manufacturing engineering, quality systems, or supply chain optimization is durable and portable across pharma/biotech.<br />
2. <strong>Build geographic expansion capability:</strong> Vaccines are expanding to 145 countries by 2030. Regional commercial/medical affairs managers who can navigate reimbursement complexity, regulatory relationships, and country-specific pricing structures are in high demand.<br />
3. <strong>Establish manufacturing leadership:</strong> Plant managers, operations directors, and manufacturing excellence leaders are durable roles with advancement to VP-level operations roles across pharma.</p>
<p><strong>Advancement timeline:</strong> Manufacturing technician ‚Üí supervisor (4-5 years) ‚Üí manager (3-4 years) ‚Üí director (3-4 years), resulting in director-level role by 12-14 years tenure. This is 2-4 year acceleration vs. historical norms.</p>
<p><strong>Compensation ceiling:</strong> ‚Ç¨140-180k base for manufacturing director roles (established by 2032). Senior operations VP roles at ‚Ç¨200-280k available for those developing broader supply chain/commercial acumen.</p>
<p><strong>External optionality:</strong> Vaccines manufacturing expertise is valued across pharma and biotech. Competitive premium available via external exit: +20-30% for experienced manufacturing managers.</p>
<h3>Tier 3: Specialty Care Division (Stable Growth, Clinical Focus)</h3>
<p><strong>Current positioning:</strong> Modest growth, clinical development pathway, moderate compensation, established career trajectories.</p>
<p><strong>Recommended positioning:</strong><br />
1. <strong>Develop therapeutic area expertise:</strong> Oncology and immunology (Dupilumab/JAK inhibitors) are high-growth therapeutic areas with durable careers. Expertise in clinical development, regulatory strategy, or medical affairs for these indications is valued.<br />
2. <strong>Build multi-indication experience:</strong> Clinical scientists who can manage trials across multiple indications (e.g., Tolima across multiple myeloma ‚Üí CLL ‚Üí lung cancer) command advancement opportunities and external premium.<br />
3. <strong>Transition to commercial medical affairs leadership:</strong> Medical affairs managers overseeing field-based oncology specialists build commercial acumen that opens CEO/COO pathways at specialty pharma or biotech.</p>
<p><strong>Advancement timeline:</strong> CRA ‚Üí Senior CRA ‚Üí Clinical trial manager ‚Üí Clinical lead ‚Üí Senior clinical scientist/director, with typical 2-3 year stepping between levels. Director-level role achievable at 14-16 year tenure (1-2 years acceleration vs. historical).</p>
<p><strong>Compensation ceiling:</strong> ‚Ç¨145-185k base for clinical directors. Senior VP clinical development roles at ‚Ç¨220-320k available for those developing broader portfolio strategy.</p>
<p><strong>External optionality:</strong> Specialty care clinical expertise is valued at competing pharma, biotech, and CROs. Compensation premium available via external exit: +15-25%.</p>
<h3>Tier 4: Generics Division (Transition Pathway)</h3>
<p><strong>Current positioning:</strong> Declining business, limited advancement, modest compensation growth, high career uncertainty.</p>
<p><strong>Strategic imperative:</strong> Generics employees should actively transition to growth businesses (vaccines, specialty care, AI discovery) by Q4 2030 or plan external exit by 2032.</p>
<p><strong>Transition recommendations:</strong><br />
1. <strong>Vaccines manufacturing:</strong> Manufacturing background is directly transferable. Generics manufacturing technicians/engineers can transition to vaccines manufacturing with 6-12 month retraining. Transition compensation bump: +8-12% (to vaccines division baseline).<br />
2. <strong>Specialty care quality/regulatory:</strong> Quality assurance and regulatory expertise is translatable to specialty care. Generics regulatory specialists can transition to specialty care regulatory roles with minimal retraining. Transition compensation bump: +6-10%.<br />
3. <strong>AI drug discovery (for quantitatively skilled):</strong> Manufacturing engineers with strong quantitative backgrounds can transition to AI/ML engineering roles (with structured reskilling 6-12 months). This is highest-upside transition, but lowest success probability (40-50% vs. 75-85% for manufacturing ‚Üí vaccines transitions).</p>
<p><strong>External exit timing:</strong> If transitioning internally is not feasible or desired, external exit is optimal by 2031-2032 (before generics business stabilizes at mature business economics). Market timing: pharma is actively hiring 2029-2031; hiring demand normalizes 2032-2033.</p>
<hr />
<h2>SECTION 4: ORGANIZATIONAL CULTURE &amp; FORWARD INDICATORS</h2>
<h3>AI Division: "Startup Within Pharma" Dynamics</h3>
<p><strong>Culture indicators (June 2030):</strong><br />
- 88% "I see myself here in 5 years" employee engagement score (vs. 62% company average)<br />
- Flat hierarchy: VP-level reports have 12-18 direct reports (vs. 6-8 across rest of company)<br />
- Publication/conference activity: 42 peer-reviewed publications by Sanofi AI division in 2029 (vs. 8 across entire company in 2025)<br />
- Attrition rate: 6-8% annually (vs. 10-12% company average), indicating strong retention</p>
<h3>Vaccines: Growth Business Momentum</h3>
<p><strong>Culture indicators:</strong><br />
- 74% engagement score (above company average)<br />
- Promotional velocity: 28% of mid-level employees promoted in FY2030 vs. 12% company average<br />
- Management quality perception: 81% of employees report "clear career path" (vs. 54% company average)<br />
- Attrition rate: 8-10% annually (competitive for pharma manufacturing)</p>
<h3>Specialty Care: Stable Growth Culture</h3>
<p><strong>Culture indicators:</strong><br />
- 62% engagement score (company average)<br />
- Promotional velocity: 18% of mid-level employees promoted<br />
- Attrition rate: 10-12% annually<br />
- Concern: clinical development employees express concern about oncology pipeline execution (worry about Tolima label expansion timelines)</p>
<h3>Generics: Declining Business Demoralization</h3>
<p><strong>Culture indicators:</strong><br />
- 28% engagement score (well below company average)<br />
- "Concern about job security" responses: 64% of generics employees (vs. 22% across rest of company)<br />
- Attrition rate: 22-24% annually (voluntary departures accelerating)<br />
- Promotion velocity: Near-zero; 0 promotions in 2029-2030</p>
<hr />
<h2>SECTION 5: FINANCIAL &amp; STOCK MARKET IMPLICATIONS</h2>
<h3>Stock Performance &amp; Valuation</h3>
<p>Sanofi stock performance (2025-2030):</p>
<ul>
<li><strong>2025:</strong> ‚Ç¨98/share</li>
<li><strong>2027:</strong> ‚Ç¨124/share (+27% from 2025, as RSV success became apparent)</li>
<li><strong>2029:</strong> ‚Ç¨168/share (+35% from 2027, as Tolima approval and AI pipeline acceleration drove investor confidence)</li>
<li><strong>June 2030:</strong> ‚Ç¨212/share (+26% from 2029)</li>
</ul>
<p><strong>Cumulative return 2025-2030:</strong> +116% (annualized +16.4%)</p>
<p><strong>Valuation multiples:</strong><br />
- <strong>P/E ratio (2030):</strong> 22.1x (vs. pharma industry 16-19x), driven by growth rate premium (8-12% revenue CAGR vs. industry 4-6%)<br />
- <strong>EV/EBITDA (2030):</strong> 12.8x (vs. industry 10-13x), reflecting normalized leverage (Net Debt/EBITDA of 1.1x)</p>
<p><strong>Analyst positioning:</strong> 72% of analyst coverage is "buy" or "outperform" (vs. 58% pharma industry average), with FY2033 price targets of ‚Ç¨285-320 (implying 35-50% upside from June 2030 price).</p>
<h3>Equity Compensation &amp; Employee Wealth Creation</h3>
<p><strong>Sanofi equity grant structure (June 2030):</strong></p>
<ul>
<li><strong>AI division:</strong> ‚Ç¨5-20k annual grant (new, introduced 2028), 3-year vesting (1/3 annually)</li>
<li><strong>Vaccines division:</strong> ‚Ç¨2-8k annual grant (2025 baseline), 4-year vesting</li>
<li><strong>Specialty care:</strong> ‚Ç¨1.5-6k annual grant (2025 baseline), 4-year vesting</li>
<li><strong>Generics division:</strong> ‚Ç¨0-1.5k annual grant (minimal), 4-year vesting</li>
</ul>
<p><strong>Employee wealth creation example (AI division, hired 2027):</strong><br />
- Year 1 (2027): ‚Ç¨8k grant (‚Ç¨150k salary), stock price ‚Ç¨148<br />
- Year 2 (2028): ‚Ç¨10k grant (‚Ç¨168k salary), stock price ‚Ç¨175<br />
- Year 3 (2029): ‚Ç¨15k grant (‚Ç¨188k salary), stock price ‚Ç¨210<br />
- Year 4 (2030): ‚Ç¨18k grant (‚Ç¨210k salary), stock price ‚Ç¨212</p>
<p><strong>Four-year total vesting value:</strong> ‚Ç¨51k in grants (assuming price stays flat). If stock appreciates to ‚Ç¨280 by 2032, vesting value becomes ‚Ç¨67k (+31%). Combined with salary growth (5-year CAGR of 9%) and bonus (18-25% of base), total compensation growth from 2027-2032: 5-year CAGR of 11-13%.</p>
<hr />
<h2>CONCLUSION: STRATEGIC INFLECTION POINT FOR SANOFI EMPLOYEES (2030-2035)</h2>
<p>Sanofi is executing fundamental portfolio transformation from "pharma consolidator" to "specialty-vaccines-AI growth company." For employees, this creates a 5-7 year window of differentiated career opportunities based on business unit alignment.</p>
<p><strong>Strategic imperatives:</strong></p>
<ol>
<li>
<p><strong>AI division employees:</strong> Maximize tenure (3-4 years) building program ownership and pharma domain expertise, then transition to external AI biotech/CTO roles. External compensation premium of +35-50% is available post-2032.</p>
</li>
<li>
<p><strong>Vaccines division employees:</strong> Build manufacturing operations or geographic commercial expertise. These careers are durable, advancement is accelerating (2-4 years compression), and external optionality (pharmaceutical/biotech) is strong.</p>
</li>
<li>
<p><strong>Specialty care employees:</strong> Develop therapeutic area expertise in high-growth indications (oncology, rare disease immunology). Advancement is steady; external optionality is moderate (+15-25% premium).</p>
</li>
<li>
<p><strong>Generics employees:</strong> Transition to growth businesses (vaccines, specialty care) by Q4 2030, or plan external exit by 2031-2032. Remaining in generics through 2032 creates career risk.</p>
</li>
</ol>
<p>The Sanofi transformation represents a rare pharmaceutical industry example of portfolio-driven workforce realignment creating clear "winners" (AI, vaccines) and "losers" (generics). Those who position early (H1 2030) will experience acceleration in advancement, compensation, and external optionality through 2035.</p>
<p><strong>The 2030 Report ‚Äî Macro Intelligence Unit</strong></p>
<hr />
<h2>WHAT YOU SHOULD DO NOW</h2>
<p>The window for proactive career management is open now but narrowing. Here's your action plan:</p>
<p><strong>Audit your role honestly:</strong> Break your job into its component tasks. Which ones could an AI system handle today? Which ones could it handle in 2-3 years? The tasks that remain ‚Äî complex judgment, relationship management, creative problem-solving, ethical decision-making ‚Äî are where you need to concentrate your value.</p>
<p><strong>Become AI-augmented, not AI-replaced:</strong> Start using AI tools in your current role today. Learn prompt engineering, AI-assisted analysis, and AI-augmented workflows. The goal is to become the person who accomplishes with AI what used to require a team of five.</p>
<p><strong>Invest in reskilling:</strong> Identify the skills that your industry will need in 2028-2030 and start building them now. Online courses, certifications, side projects ‚Äî the investment is small compared to the cost of being displaced.</p>
<p><strong>Negotiate from strength:</strong> If your company is investing in AI transformation, volunteer for AI pilot projects. If they're not investing, that's a signal about your long-term job security there.</p>
<p><strong>Build your network:</strong> In a disrupted labor market, who you know matters more than ever. Build relationships across your industry, especially with people at companies that are leading AI transformation.</p>
<p><strong>Have a financial buffer:</strong> Save aggressively. If your role is at risk, having 6-12 months of expenses saved gives you the freedom to retrain or transition on your own terms rather than under duress.</p>
<p><em>Read more: Browse all <a href="/browse/sectors.html">Employee-focused memos</a> across 20 sectors to understand how your specific industry is being transformed.</em></p>
            </div>
        </article>

        <div style="margin-top: 3rem; padding-top: 2rem; border-top: 1px solid var(--border); text-align: center;"><a href="/browse/companies/sanofi.html" style="display: inline-block; padding: 1rem 2rem; background: var(--bg-card); border: 1px solid var(--border); border-radius: 0.5rem; color: var(--text-primary); font-weight: 600; transition: all 0.2s ease;">‚Üê All Sanofi Articles</a></div>
        
        <div class="more-in-category">
            <h3>More in Companies</h3>
            <div class="more-grid">
                
            <div class="more-card">
                <h4>ENTITY: APPLE CORPORATION</h4>
                <p>FROM: The 2030 Report, Technology & Market Analysis Division</p>
                <a href="/articles/companies-us-apple-apple-ceo.html">Read more ‚Üí</a>
            </div>
            
            <div class="more-card">
                <h4>ENTITY: APPLE INC.</h4>
                <p>From: The 2030 Report Global Intelligence Division</p>
                <a href="/articles/companies-us-apple-apple-investor.html">Read more ‚Üí</a>
            </div>
            
            <div class="more-card">
                <h4>ENTITY: APPLE INC.</h4>
                <p>---</p>
                <a href="/articles/companies-us-apple-apple-employee.html">Read more ‚Üí</a>
            </div>
            
            <div class="more-card">
                <h4>ENTITY: THE HOME DEPOT INC.</h4>
                <p>FROM: The 2030 Report</p>
                <a href="/articles/companies-us-home-depot-home-depot-ceo.html">Read more ‚Üí</a>
            </div>
            
            <div class="more-card">
                <h4>HOME DEPOT: WORKFORCE RESTRUCTURING IN HOUSING DOWNTURN</h4>
                <p>FROM: The 2030 Report</p>
                <a href="/articles/companies-us-home-depot-home-depot-employee.html">Read more ‚Üí</a>
            </div>
            
            <div class="more-card">
                <h4>ENTITY: Home Depot, Inc. | Housing Market Downturn and Structural Retail Transformation</h4>
                <p>FROM: The 2030 Report | Retail and Consumer Spending Analysis</p>
                <a href="/articles/companies-us-home-depot-home-depot-investor.html">Read more ‚Üí</a>
            </div>
            
            </div>
        </div>
        

        <!-- Feedback Widget -->
        <div class="feedback-widget" id="feedbackWidget">
            <button class="feedback-toggle" onclick="toggleFeedback()" aria-label="Report an issue or send feedback">
                üí¨ Feedback
            </button>
            <div class="feedback-panel" id="feedbackPanel">
                <div class="feedback-header">
                    <h3>Send Feedback</h3>
                    <button class="feedback-close" onclick="toggleFeedback()">‚úï</button>
                </div>
                <form class="feedback-form" id="feedbackForm" onsubmit="submitFeedback(event)">
                    <input type="hidden" name="page_url" id="feedbackPageUrl">
                    <div class="feedback-field">
                        <label>Type</label>
                        <div class="feedback-type-btns">
                            <label class="feedback-type-label"><input type="radio" name="type" value="Error" required> üêõ Error</label>
                            <label class="feedback-type-label"><input type="radio" name="type" value="Suggestion"> üí° Suggestion</label>
                            <label class="feedback-type-label"><input type="radio" name="type" value="Other"> üìù Other</label>
                        </div>
                    </div>
                    <div class="feedback-field">
                        <label for="feedbackMsg">Message</label>
                        <textarea id="feedbackMsg" name="message" rows="3" placeholder="Tell us what's wrong or how we can improve..." required></textarea>
                    </div>
                    <div class="feedback-field">
                        <label for="feedbackEmail">Your Email (optional)</label>
                        <input type="email" id="feedbackEmail" name="email" placeholder="your@email.com">
                    </div>
                    <button type="submit" class="feedback-submit">Send Feedback</button>
                </form>
                <div class="feedback-success" id="feedbackSuccess" style="display:none;">
                    <div style="font-size:2rem;">‚úÖ</div>
                    <p>Thank you! Your email client will open with the feedback.</p>
                </div>
            </div>
        </div>

    </main>

    <footer class="site-footer">
        <div class="footer-content">
            <div class="footer-disclaimer">
                <strong>Disclaimer:</strong> This report provides forecasts and analysis of AI disruption trends. Predictions are based on current data and expert analysis but are subject to change. Use this information for informational purposes only.
            </div>
            <div class="footer-links">
                <a href="/">Home</a>
                <a href="/browse/countries.html">Countries</a>
                <a href="/browse/companies.html">Companies</a>
                <a href="/browse/sectors.html">Sectors</a>
                <a href="/government.html">Government</a>
                <a href="/press.html">Press</a>
                <a href="/about.html">About</a>
            </div>
            <div style="color: var(--text-muted); font-size: 0.85rem; margin-top: 1rem;">
                &copy; 2030 Intelligence Report. All rights reserved.
            </div>
        </div>
    </footer>

    <button class="back-to-top" onclick="scrollToTop()" title="Back to top">‚Üë</button>

    <script>
        function toggleNav() {
            const navLinks = document.querySelector('.nav-links');
            navLinks.classList.toggle('active');
        }
        // Highlight active nav item
        document.querySelectorAll('.nav-links a').forEach(link => {
            const href = link.getAttribute('href');
            const path = window.location.pathname;
            if (href === '/' && path === '/') link.classList.add('nav-active');
            else if (href !== '/' && path.startsWith(href.replace('.html', ''))) link.classList.add('nav-active');
        });

        function scrollToTop() {
            window.scrollTo({ top: 0, behavior: 'smooth' });
        }

        function copyLink(e) {
            const url = window.location.href;
            const btn = e.currentTarget;
            navigator.clipboard.writeText(url).then(() => {
                const originalText = btn.innerText;
                btn.innerText = '‚úì Copied!';
                btn.classList.add('copied');
                setTimeout(() => {
                    btn.innerText = originalText;
                    btn.classList.remove('copied');
                }, 2000);
            });
        }

        const pageTitle = document.title.split(' - ')[0];

        function shareOnTwitter() {
            const url = window.location.href;
            const text = encodeURIComponent(pageTitle + ' ‚Äî ' + url);
            window.open(`https://twitter.com/intent/tweet?text=${text}`, '_blank');
        }

        function shareOnLinkedIn() {
            const url = window.location.href;
            window.open(`https://www.linkedin.com/sharing/share-offsite/?url=${encodeURIComponent(url)}`, '_blank');
        }

        function shareOnFacebook() {
            const url = window.location.href;
            window.open(`https://www.facebook.com/sharer/sharer.php?u=${encodeURIComponent(url)}`, '_blank');
        }

        function shareOnWhatsApp() {
            const url = window.location.href;
            const text = encodeURIComponent(pageTitle + ' ‚Äî ' + url);
            window.open(`https://wa.me/?text=${text}`, '_blank');
        }

        function shareViaEmail() {
            const url = window.location.href;
            window.location.href = `mailto:?subject=${encodeURIComponent(pageTitle)}&body=${encodeURIComponent('Check this out: ' + url)}`;
        }

        window.addEventListener('scroll', () => {
            const backToTop = document.querySelector('.back-to-top');
            if (window.scrollY > 300) {
                backToTop.classList.add('visible');
            } else {
                backToTop.classList.remove('visible');
            }
        });

        document.querySelectorAll('a[href^="#"]').forEach(anchor => {
            anchor.addEventListener('click', function(e) {
                e.preventDefault();
                const target = document.querySelector(this.getAttribute('href'));
                if (target) {
                    target.scrollIntoView({ behavior: 'smooth' });
                }
            });
        });

        // Feedback widget
        document.getElementById('feedbackPageUrl').value = window.location.href;
        function toggleFeedback() {
            document.getElementById('feedbackPanel').classList.toggle('open');
        }
        window.toggleFeedback = toggleFeedback;

        function submitFeedback(e) {
            e.preventDefault();
            const form = document.getElementById('feedbackForm');
            const type = form.querySelector('input[name="type"]:checked');
            const msg = document.getElementById('feedbackMsg').value;
            const email = document.getElementById('feedbackEmail').value;
            const pageUrl = window.location.href;
            const subject = encodeURIComponent('[AI 2030 Report] ' + (type ? type.value : 'Feedback') + ': ' + document.title.split(' - ')[0]);
            const body = encodeURIComponent(
                'Type: ' + (type ? type.value : 'N/A') + '\n' +
                'Page: ' + pageUrl + '\n' +
                'From: ' + (email || 'Anonymous') + '\n\n' +
                'Message:\n' + msg
            );
            window.location.href = 'mailto:narenbizymoms@gmail.com?subject=' + subject + '&body=' + body;
            form.style.display = 'none';
            document.getElementById('feedbackSuccess').style.display = 'block';
            setTimeout(() => {
                document.getElementById('feedbackPanel').classList.remove('open');
                setTimeout(() => {
                    form.style.display = '';
                    form.reset();
                    document.getElementById('feedbackSuccess').style.display = 'none';
                }, 300);
            }, 2000);
        }
        window.submitFeedback = submitFeedback;
    </script>
</body>
</html>
